• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eurosurv: Age-related prevalence of cross-reactive antibodies against influenza A(H3N2) variant virus, Germany, 2003 to 2010

tetano

Editor, Senior Moderator
Eurosurveillance, Volume 20, Issue 32, 13 August 2015
Research articles
Age-related prevalence of cross-reactive antibodies against influenza A(H3N2) variant virus, Germany, 2003 to 2010
B Bl?mel ()[SUP]1[/SUP][SUP],2[/SUP][SUP],3[/SUP][SUP],4[/SUP], B Schweiger[SUP]1[/SUP], M Dehnert[SUP]1[/SUP][SUP],5[/SUP], S Buda[SUP]1[/SUP], A Reuss[SUP]1[/SUP], I Czogiel[SUP]1[/SUP], P Kamtsiuris[SUP]1[/SUP], M Schlaud[SUP]1[/SUP], C Poethko-M?ller[SUP]1[/SUP], M Thamm[SUP]1[/SUP], W Haas[SUP]1[/SUP]
  • Robert Koch Institute, Berlin, Germany
  • Postgraduate Training for Applied Epidemiology (PAE, German FETP), Robert Koch-Institute, Berlin, Germany
  • European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
  • Current affiliation: Institute of Medical Microbiology and Hygiene, University Medical Center Freiburg, Freiburg, Germany
  • Current affiliation: Department of Biotechnology and Bioinformatics, Weihenstephan-Triesdorf University of Applied Sciences, Freising, Germany

Citation style for this article: Bl?mel B, Schweiger B, Dehnert M, Buda S, Reuss A, Czogiel I, Kamtsiuris P, Schlaud M, Poethko-M?ller C, Thamm M, Haas W. Age-related prevalence of cross-reactive antibodies against influenza A(H3N2) variant virus, Germany, 2003 to 2010. Euro Surveill. 2015;20(32):pii=21206. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21206
Date of submission: 15 September 2014

[SIZE=+0]To estimate susceptibility to the swine-origin influenza A(H3N2) variant virus (A(H3N2)v) in the German population, we investigated cross-reactive antibodies against this virus and factors associated with seroprotective titre using sera from representative health examination surveys of children and adolescents (n = 815, 2003?06) and adults (n = 600, 2008?10). Antibodies were assessed by haemagglutination inhibition assay (HI); in our study an HI titre ≥ 40 was defined as seroprotective. We investigated associated factors by multivariable logistic regression. Overall, 41% (95% confidence interval (CI): 37?45) of children and adolescents and 39% (95% CI: 34?44) of adults had seroprotective titres. The proportion of people with seroprotective titre was lowest among children younger than 10 years (15%; 95% CI: 7?30) and highest among adults aged 18 to 29 years (59%; 95% CI: 49?67). Prior influenza vaccination was associated with higher odds of having seroprotective titre (odds ratio (OR) for children and adolescents: 3.4; 95% CI: 1.8?6.5; OR for adults: 2.4; 95% CI: 1.7?3.4). Young children showed the highest and young adults the lowest susceptibility to the A(H3N2)v virus. Our results suggest that initial exposure to circulating seasonal influenza viruses may predict long-term cross-reactivity that may be enhanced by seasonal influenza vaccination. [/SIZE]


http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21206
 
Back
Top Bottom